

You are cordially invited to attend an educational presentation:

## ORSERDU™ (elacestrant)

The first and only therapy indicated for ER+/HER2- *ESR1*-mutated mBC following at least one line of endocrine therapy



### Presented by:

**Hope Rugo, MD, FASCO**

Professor of Medicine

Director, Breast Oncology and Clinical Trials Education

UCSF Helen Diller Family Comprehensive Cancer Center  
San Francisco, CA

### Product Theater

**Friday, February 24, 2023**

**11:00am - 11:45am HST**

**Conference Room: Honolulu 1**

**Hilton Hawaiian Village**

**Honolulu, Hawaii**

### Indication

ORSERDU (elacestrant) 345 mg tablets are indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, *ESR1*-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

### Important Safety Information

- **Dyslipidemia:** Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively. The incidence of Grade 3 and 4 hypercholesterolemia and hypertriglyceridemia were 0.9% and 2.2%, respectively. Monitor lipid profile prior to starting and periodically while taking ORSERDU.

**Please see Important Safety Information on the next page and click here for Full Prescribing Information**

## Important Safety Information (Continued)

- **Embryo-Fetal Toxicity:** Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose.

## Adverse Reactions

- **Serious adverse reactions** occurred in 12% of patients who received ORSERDU. Serious adverse reactions in >1% of patients who received ORSERDU were musculoskeletal pain (1.7%) and nausea (1.3%). Fatal adverse reactions occurred in 1.7% of patients who received ORSERDU, including cardiac arrest, septic shock, diverticulitis, and unknown cause (one patient each).
- The most common adverse reactions ( $\geq 10\%$ ), including laboratory abnormalities, of ORSERDU were musculoskeletal pain (41%), nausea (35%), increased cholesterol (30%), increased AST (29%), increased triglycerides (27%), fatigue (26%), decreased hemoglobin (26%), vomiting (19%), increased ALT (17%), decreased sodium (16%), increased creatinine (16%), decreased appetite (15%), diarrhea (13%), headache (12%), constipation (12%), abdominal pain (11%), hot flush (11%), and dyspepsia (10%).

## Drug Interactions

- **Concomitant use with CYP3A4 inducers and/or inhibitors:** Avoid concomitant use of strong or moderate CYP3A4 inhibitors with ORSERDU. Avoid concomitant use of strong or moderate CYP3A4 inducers with ORSERDU.

## Use in Specific Populations

- **Lactation:** Advise lactating women to not breastfeed during treatment with ORSERDU and for 1 week after the last dose.
- **Hepatic Impairment:** Avoid use of ORSERDU in patients with severe hepatic impairment (Child-Pugh C). Reduce the dose of ORSERDU in patients with moderate hepatic impairment (Child-Pugh B).

The safety and effectiveness of ORSERDU in pediatric patients have not been established.

**To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

**[Please click here for Full Prescribing Information](#)**

This program is a Stemline sponsored promotional program. Stemline will report all transfers of value related to meals provided to you as required by applicable national, territorial and/or state transparency laws and regulations. In most cases, the information will be published. Minnesota, Vermont, the Department of Defense, and the Department of Veteran Affairs have regulations or policies that prohibit the receipt of meals at company sponsored events. You are accountable for understanding such restrictions and complying with them, and Stemline may restrict your participation at this program. You may choose to opt out of the meal. Please note, we are unable to accommodate spouses or guests at this event.



© 2023 Stemline Therapeutics, Inc., a Menarini Group Company  
ORSERDU is a trademark of the Menarini Group  
All rights reserved. 01/2023 ELA- 05146

